The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 511-519

  Zhu, Rui ^a   Kiser, Jennifer J ^b   Seifart, Heiner I ^c   Werely, Cedric J ^c   Mitchell, Charles D ^d   D'Argenio, David Z ^a   Fletcher, Courtney V ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

enzyme maturation; genetic polymorphism; Infants; pharmacogenetics; population pharmacokinetics

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID;

ARTICLE; BODY WEIGHT; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; PERINATAL DRUG EXPOSURE; PERINATAL PERIOD; PHARMACOGENETICS; POPULATION RESEARCH; SOUTH AFRICA; TUBERCULOSIS;

ADMINISTRATION, ORAL; AGE FACTORS; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; ISONIAZID; LATENT TUBERCULOSIS; MALE; PHARMACOGENETICS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; SOUTH AFRICA; TUBERCULOSIS;

EID: 84859012001     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011402826     Document Type: Article

References (31)

1. Wilkinson D, Davies GR. Pediatric tuberculosis in rural South Africa - value of directly observed therapy. J Trop Pediatr. 1998;44: 266-269. (Pubitemid 28477161)
2. Lalloo UG, Pillay S. Managing tuberculosis and HIV in sub-Sahara Africa. Curr HIV/AIDS Rep. 2008;5:132-139.
3. Robitzek EH, Selikoff IJ. Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report. Am Rev Tuberc. 1952;65:402-428.
4. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979;4:401-422.
5. Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997;155:1717-1722. (Pubitemid 27216683)
6. Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics. 2001;11:207-215. (Pubitemid 32319870)
7. Butcher NJ, Tiang J, Minchin RF. Regulation of arylamine N-acetyltransferases. Curr Drug Metab. 2008;9:498-504.
8. Pariente-Khayat A, Rey E, Gendrel D, et al. Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther. 1997;62:377-383. (Pubitemid 27475221)
9. Rey E, Gendrel D, Treluyer JM, et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam Clin Pharmacol. 2001;15:355-359. (Pubitemid 34037826)
10. Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005;90:614-618. (Pubitemid 40780724)
11. Seifart HI, Gent WL, Parkin DP, Donald PR. HPLC determination of isoniazid, acetylisoniazid, and hydrazine concentrations in plasma samples from TB patients. Tuber Lung Dis. 1994;75(suppl 1):61-62.
12. Seifart HI, Gent WL, Parkin DP, van Jaarsveld PP, Donald PR. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J Chromatogr B Biomed Appl. 1995;674:269-275. (Pubitemid 26005467)
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
14. Hickman D, Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol. 1991;42:1007-1014.
15. Bassam BJ, Caetano-Anollés G, Gresshoff PM. Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem. 1991;196:80-83.
16. Beal SL, Sheiner LB. NONMEM User's Guide. NONMEM Project Group. San Francisco: University of California; 1992.
17. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should weuse N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49:1733-1738. (Pubitemid 40631582)
18. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 1997;41: 2670-2679. (Pubitemid 27524738)
19. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-332. (Pubitemid 351738156)
20. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol. 2007;63:75-84. (Pubitemid 44902880)
21. Menon-Andersen D, Mondick JT, Jayaraman B, et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009;63:229-238.
22. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Population Pharmacokinetics. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 1999.
23. Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm. 1990;18:161-173. (Pubitemid 20207828)
24. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24:153-172. (Pubitemid 26300483)
25. Burk O, Wojnowski L. Cytochrome P450 3Aand their regulation. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:105-124. (Pubitemid 38161227)
26. Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Curr Drug Metab. 2009;10:567-578.
27. Hsu MH, Savas U, Griffin KJ, Johnson EF. Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev. 2007;39:515-538. (Pubitemid 47355735)
28. Oesch-Bartlomowicz B, Oesch F. Phosphorylation of cytochromes P450: first discovery of a posttranslational modification of a drug-metabolizing enzyme. Biochem Biophys Res Commun. 2005;338:446-449. (Pubitemid 41540588)
29. Stevens JC. New perspectives onthe impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov Today. 2006;11:440-445.
30. Choudhary D, Jansson I, Sarfarazi M, Schenkman JB. Xenobiotic- metabolizing cytochromes P450 in ontogeny: evolving perspective. Drug Metab Rev. 2004;36:549-568. (Pubitemid 39453062)
31. Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW. Identification of N-acetyltransferase 2(NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos. 2007;35:721-727. (Pubitemid 46641541)